Cited by 336Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 279 of the 282 references it cites were found in a registry or an index.

High-density lipoproteins: A consensus statement from the National Lipid Association

Toth, Peter P., Barter, Philip J., Rosenson, Robert S., Boden, William E., Chapman, M. John, Cuchel, Marina, D'Agostino, Ralph B., Davidson, Michael H., Davidson, W. Sean, Heinecke, Jay W., Karas, Richard H., Kontush, Anatol, Krauss, Ronald M., Miller, Michael, Rader, Daniel J.·2013·Journal of Clinical Lipidology

DOI 10.1016/j.jacl.2013.08.001

Open this paper in CoChat — free account

Abstract

For >4 decades it has been recognized that elevated serum levels of high-density lipoprotein cholesterol (HDL-C) are associated with reduced risk of cardiovascular disease (CVD) and its sequelae. Many prospective observational studies performed around the world have confirmed an inverse relationship between HDL-C and cardiovascular risk in people irrespective of sex, race, or ethnicity. Consequently, it was assumed that, by extension, raising HDL-C through lifestyle modification and pharmacologic intervention would reduce risk of CVD. Animal studies are consistent with this assumption. Lipid treatment guidelines around the world promoted the recognition of HDL-C as a therapeutic target, especially in high-risk patients. Some post hoc analyses from randomized controlled trials also suggest that raising HDL-C beneficially affects the risk of CVD. However, a number of recent randomized studies putatively designed to test the "HDL hypothesis" have failed to show benefit. The results of these trials have caused many clinicians to question whether HDL-C is a legitimate therapeutic target. In response to the many questions and uncertainties raised by the results of these trials, the National Lipid Association convened an expert panel to evaluate the current status of HDL-C as a therapeutic target; to review the current state of knowledge of HDL particle structure, composition, and function; and to identify the salient questions yet to be answered about the role of HDL in either preventing or contributing to atherosclerotic disease. The expert panel's conclusions and clinical recommendations are summarized herein. The panel concludes that, although low HDL-C identifies patients at elevated risk, and much investigation suggests that HDL may play a variety of antiatherogenic roles, HDL-C is not a therapeutic target at the present time. Risk stratified atherogenic lipoprotein burden (low-density lipoprotein cholesterol and non-HDL-C) should remain the primary and secondary targets of therapy in patients at risk, as described by established guidelines. The National Lipid Association emphasizes that rigorous research into the biology and clinical significance of low HDL-C should continue. The development of novel drugs designed to modulate the serum levels and functionality of HDL particles should also continue. On the basis of an enormous amount of basic scientific and clinical investigation, a considerable number of reasons support the need to continue to investigate the therapeutic effect of modulating HDL structure and function.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2013.08.001

Cites

279 of 279 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–279 of 279

Lipoproteomics I: Mapping of proteins in low‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry
Karlsson, H., Leanderson, P., Tagesson, C., & Lindahl, M. G. (2005) · PROTEOMICS · doi:10.1002/pmic.200300938 · Cited by 128
Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity
Souza, J. A., Vindis, C., Hansel, B., Nègre‐Salvayre, A., Thérond, P., Junior, C. V. S., Chantepie, S., Salvayre, R., Bruckert, É., Chapman, M. J., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.009 · Cited by 125
Self-citation
High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis
Nofer, J., Brodde, M. F., & Kehrel, B. E. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05377.x · Cited by 122
CORONARY ARTERIOGRAPHY IN THE STUDY OF THE EPIDEMIOLOGY OF CORONARY ARTERY DISEASE1
Pearson, T. A. (1984) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036269 · Cited by 121
Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias
Dawson, G., Kruski, A. W., & Scanu, A. M. (1976) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36996-0 · Cited by 114
Apolipoproteins A‐I and A‐II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio
Concha, M. I., Smith, V. J., Castro, K., Bastías, A., Romero, A., & Amthauer, R. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04228.x · Cited by 113
Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: Evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish
Villarroel‐Espíndola, F., Bastías, A., Casado, A., Amthauer, R., & Concha, M. I. (2006) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2006.10.008 · Cited by 113
The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins.
Davidson, W. S., Sparks, D. L., Lund‐Katz, S., & Phillips, M. C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37061-8 · Cited by 112
Self-citation
Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.
Liu, A. C., Lawn, R. M., Verstuyft, J. G., & Rubin, E. M. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39932-6 · Cited by 107
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma.
James, R. W., Hochstrasser, D. F., Tissot, J., Funk, M., Appel, R. D., Barja, F., Pellegrini, C., Muller, A. F., & Pometta, D. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38408-x · Cited by 106
Cardiolipin is a normal component of human plasma lipoproteins
Deguchi, H., Fernández, J. A., Hackeng, T. M., Banka, C. L., & Griffin, J. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1743 · Cited by 105
Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease
Miller, M. J., Mead, L. A., Kwiterovich, P. O., & Pearson, T. A. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90017-u · Cited by 104
Self-citation
Atheroprotective Effects of High-Density Lipoprotein-Associated Lysosphingolipids
Nofer, J., & Assmann, G. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.08.005 · Cited by 103
Effects of orientational order and particle size on the NMR line positions of lipoproteins
Lounila, J., Ala‐Korpela, M., Jokisaari, J. P., Savolainen, M. J., & Kesäniemi, Y. A. (1994) · Physical Review Letters · doi:10.1103/physrevlett.72.4049 · Cited by 101
Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr
Ståhlman, M., Davidsson, P., Kanmert, I., Rosengren, B. E., Borén, J., Fagerberg, B., & Camejo, G. (2007) · Journal of Lipid Research · doi:10.1194/jlr.d700025-jlr200 · Cited by 98
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)
Vinall, M., & Collins, R. (2009) · MD Conference Express · doi:10.1177/155989770900800804 · Cited by 97
Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice
Li, Y., Dong, J., & Wu, M.-P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.047 · Cited by 94
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Krauss, R. M., Wojnooski, K., Orr, J., Geaney, J. C., Pinto, C. A., Liu, Y., Wagner, J. A., Luk, J. A. M., Johnson‐Levonas, A. O., Anderson, M. S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m018010 · Cited by 94
Self-citation
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 93
Self-citation
High-density lipoprotein and the acute phase response
Jahangiri, A. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328337278b · Cited by 92
Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry
Scherer, M., Böttcher, A., Schmitz, G., & Liebisch, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.11.003 · Cited by 91
Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort
Williams, P. T., & Feldman, D. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.024 · Cited by 90
Role of Apolipoprotein A-I in Protecting against Endotoxin Toxicity
Ma, J., Liao, X., Lou, B., & Wu, M.-P. (2004) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/36.6.419 · Cited by 90
The concept of apolipoprotein-defined lipoprotein families and its clinical significance
Alaupovic, P. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0036-8 · Cited by 84
Mass spectrometry‐based analytical tools for the molecular protein characterization of human plasma lipoproteins
Heller, M., Stalder, D., Schlappritzi, E., Hayn, G., Matter, U., & Haeberli, A. (2005) · PROTEOMICS · doi:10.1002/pmic.200401233 · Cited by 83
HDL in humans with cardiovascular disease exhibits a proteomic signature
Vaisar, T., Mayer, P. S., Nilsson, E. J., Zhao, X. Q., Knopp, R. H., & Prazen, B. J. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.03.023 · Cited by 80
Fate of intravenously administered particulate and lipoprotein cholesterol in the rat
Nilason, Å., & Zilversmit, D. B. (1972) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39433-5 · Cited by 80
Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
Castro‐Perez, J. M., Briand, F., Gagen, K., Wang, S., Chen, Y., McLaren, D. G., Shah, V., Vreeken, R. J., Hankemeier, T., Sulpice, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016410 · Cited by 78
Separation and analysis of lipoproteins by gel filtration
Rudel, L. L., Marzetta, C. A., & Johnson, F. L. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)29061-8 · Cited by 76
Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease
Romm, P. A., Green, C. E., Reagan, K., & Rackley, C. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90007-8 · Cited by 75
Measurement of Reverse Cholesterol Transport Pathways in Humans: In Vivo Rates of Free Cholesterol Efflux, Esterification, and Excretion
Turner, S., Voogt, J. N., Davidson, M. H., Glass, A., Killion, S., Decaris, J., Mohammed, H., Minehira, K., Boban, D., Murphy, E. J., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001826 · Cited by 73
Self-citation
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol
The AIM-HIGH Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.017 · Cited by 72
HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach
Mangé, A., Goux, A., Badiou, S., Patrier, L., Canaud, B., Maudelondé, T., Cristol, J., & Solassol, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034107 · Cited by 71
High‐Density Lipoproteins
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678 · Cited by 68
Self-citation
Niacin and biosynthesis of PGD2 by platelet COX-1 in mice and humans
Song, W., Stubbe, J., Ricciotti, E., Alamuddin, N., Ibrahim, S. A., Crichton, I., Prempeh, M., Lawson, J. A., Wilensky, R. L., Rasmussen, L. M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59262 · Cited by 68
Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels
Ginsburg, G. S., Safran, C., & Pasternak, R. C. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90742-4 · Cited by 67
Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency
Santos, R. D., Schaefer, E. J., Asztalos, B. F., Polisecki, E. Y., Wang, J., Hegele, R. A., Martinez, L. R. C., Miname, M. H., Rochitte, C. E., da Luz, P. L., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700362-jlr200 · Cited by 65
Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid
Jiao, Y.-L., & Wu, M.-P. (2008) · Cytokine · doi:10.1016/j.cyto.2008.04.002 · Cited by 65
Pharmacologic Suppression of Hepatic ATP-Binding Cassette Transporter 1 Activity in Mice Reduces High-Density Lipoprotein Cholesterol Levels but Promotes Reverse Cholesterol Transport
Yamamoto, S., Tanigawa, H., Li, X., Komaru, Y., Billheimer, J. T., & Rader, D. J. (2011) · Circulation · doi:10.1161/circulationaha.110.009704 · Cited by 65
Self-citation
Diverse range of small peptides associated with high-density lipoprotein
Hortin, G. L., Shen, R., Martin, B. M., & Remaley, A. T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.098 · Cited by 63
Molecular Mechanism of Reverse Cholesterol Transport: Reaction of Pre-β-Migrating High-Density Lipoprotein with Plasma Lecithin/Cholesterol Acyltransferase
Nakamura, Y., Kotite, L., Gan, Y., Spencer, T. A., Fielding, C. J., & Fielding, P. E. (2004) · Biochemistry · doi:10.1021/bi0485629 · Cited by 62
Clinical Lipidology: A Companion to Braunwald's Heart Disease
Ballantyne, C. M. (2014) · Cited by 61
Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate.
Schwartz, C. C., Zech, L. A., VandenBroek, J. M., & Cooper, P. S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116314 · Cited by 61
The protein cargo of HDL: Implications for vascular wall biology and therapeutics
Heinecke, J. W. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.005 · Cited by 59
Self-citation
Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway
Nakaya, K., Tohyama, J., Naik, S. U., Tanigawa, H., Macphee, C. H., Billheimer, J. T., & Rader, D. J. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.225383 · Cited by 54
Self-citation
S1P and eNOS regulation
IGARASHI, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.06.008 · Cited by 53
Proteomic analysis of human very low‐density lipoprotein by two‐dimensional gel electrophoresis and MALDI‐TOF/TOF
Mancone, C., Amicone, L., Fimia, G. M., Bravo, E., Piacentini, M., Tripodi, M., & Alonzi, T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600339 · Cited by 51
Apolipoprotein A-I from striped bass (Morone saxatilis) demonstrates antibacterial activity in vitro
Johnston, L. D., Brown, G. D., Gauthier, D. T., Reece, K. S., Kator, H. I., & Veld, P. V. (2008) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2008.06.011 · Cited by 49
Clinical Lipidology: A Companion to Braunwald's Heart Disease
van Heyningen, C. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.200917 · Cited by 49
Multicompartmental Analysis of Cholesterol Metabolism in Man
Schwartz, C. C., Berman, M., Vlahčevič, Z. R., & Swell, L. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110683 · Cited by 48
A Prospective Study of High-Density Lipoprotein Cholesterol, Cholesteryl Ester Transfer Protein Gene Variants, and Healthy Aging in Very Old Japanese-American Men
Koropatnick, T. A., Kimbell, J., Chen, R., Grove, J., Donlon, T. A., Masaki, K., Rodríguez, B. L., Willcox, B. J., Yano, K., & Curb, J. D. (2008) · The Journals of Gerontology Series A · doi:10.1093/gerona/63.11.1235 · Cited by 46
Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology
Kulkarni, K. R., Marcovina, S. M., Krauss, R. M., Garber, D. W., Glasscock, A. M., & Segrest, J. P. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34949-x · Cited by 45
Self-citation
Inflammation and skin cholesterol in LDLr−/−, apoA-I−/− mice: link between cholesterol homeostasis and self-tolerance?
Zabalawi, M., Bharadwaj, M. S., Horton, H., Cline, M., Willingham, M. C., Thomas, M. J., & Sorci‐Thomas, M. G. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600370-jlr200 · Cited by 43
Lipoprotein electrostatic properties regulate hepatic lipase association and activity
Boucher, J. G., Nguyen, T., & Sparks, D. L. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-137 · Cited by 41
Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity
Arai, Y., Hirose, N., Yamamura, K., Nakazawa, S., Shimizu, K.-I., Takayama, M., Ebihara, Y., Homma, S., Gondo, Y., Masui, Y., et al. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0407-6 · Cited by 41
Comparison of risk profiles for cardiovascular events: implications for prevention.
Wb, K., & Pw, W. (1997) · PubMed · Cited by 41
HDL Metabolism and Atherosclerosis
Assmann, G., & Funke, H. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199000169-00004 · Cited by 40
Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction A 10-year Familial Atherosclerosis Treatment Study follow-up
Brown, B. G., Brockenbrough, A., Zhao, X., Dowdy, A. A., Monick, E. A., Frechette, E. E. H. S., Poulin, D., & Rocha, A. (1998) · Cited by 40
Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation
Matsuo, Y., Miura, S.-I., Kawamura, A., Uehara, Y., Rye, K., & Saku, K. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.10.020 · Cited by 38
Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography–tandem mass spectrometry
Lee, J. Y., Min, H. K., Choi, D., & Moon, M. H. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.01.006 · Cited by 38
Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity
Rubinow, K. B., Vaisar, T., Tang, C., Matsumoto, A. M., Heinecke, J. W., & Page, S. T. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p026005 · Cited by 37
Self-citation
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence
Brown, B. G., Zhao, X.-Q., & Cheung, M. C. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.004 · Cited by 36
HDL Metabolism and Atherosclerosis
Assmann, G., & Funke, H. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199006169-00004 · Cited by 33
Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation
Cone, J. T., Segrest, J. P., Chung, B. H., Ragland, J. B., Sabesin, S. M., & Glasscock, A. M. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38096-2 · Cited by 32
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies
Meyers, C. D., & Kashyap, M. L. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.hco.0000167718.30076.24 · Cited by 29
Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study.
Wilson, P. W. F., & Kannel, W. B. (1993) · PubMed · Cited by 28
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
Younk, L. M., Uhl, L., & Davis, S. N. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.579561 · Cited by 26
The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease
Rhyne, J., Ryan, M. J., White, C., Chimonas, T., & Miller, M. J. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0070-4 · Cited by 26
Self-citation
Distribution of diacylglycerols among plasma lipoproteins in control subjects and in patients with non‐insulin‐dependent diabetes
Lalanne, F., Pruneta‐Deloche, V., Bernard, S., & Ponsin, G. (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00438.x · Cited by 24
Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men
Rubinow, K. B., Tang, C., Hoofnagle, A. N., Snyder, C. N., Amory, J. K., Heinecke, J. W., & Page, S. T. (2012) · Steroids · doi:10.1016/j.steroids.2012.01.002 · Cited by 21
Self-citation
Protein profiling of low‐density lipoprotein from obese subjects
Karlsson, H., Mörtstedt, H., Lindqvist, H. M., Tagesson, C., & Lindahl, M. G. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800138 · Cited by 21
The difficult search for a ‘partner’ of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin
Landmesser, U. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht064 · Cited by 21
The surprising AIM-HIGH results are not surprising when viewed through a particle lens
Otvos, J. D. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.012 · Cited by 18
Advances in Internal Medicine.
(1943) · Archives of Internal Medicine · doi:10.1001/archinte.1943.00210020164011 · Cited by 13
Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenicEscherichia coli
FigueirÃado, P. M. S., Catani, C. F., & Yano, T. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00125-1 · Cited by 12
QUANTITATIVE KINETIC EVALUATION OF PRECURSOR SOURCES AND TURNOVER OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL ESTERS
Schwartz, C. C., Berman, M., Vlahčevič, Z. R., & Swell, L. (1982) · Cited by 6
Factors influencing coronary risk in low HDL syndromes
Miller, M. J., & Zhan, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00152-7 · Cited by 3
Self-citation
Abstract 71: Assessment of Reverse Cholesterol Transport in Vivo in Humans: A Novel Method
Cuchel, M., Billheimer, J. T., Millar, J. S., Schwartz, C. C., Raper, A. C., Ochotny, R., Baer, A. L., Su, C., Carlsson, B., & Rader, D. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvb.32.suppl_1.a71 · Cited by 3
Self-citation
In vivo Tissue Cholesterol Efflux is Impaired in Carriers of Mutations in APOA1 and ABCA1
Holleboom, A. G., Franssen, R., Jakulj, L., Decaris, J., Vergeer, M., Koetsveld, J., Hellerstein, M. K., Kastelein, J. J. P., Groen, A. K., Turner, S., et al. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2

Flagged first, then by citations

3 of the 282 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Morse, 2001, Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose, J Am Coll Cardiol, 37, 262A
Kannel, 1992, Efficacy of lipid profiles in prediction of coronary disease, Am Heart J, 124, 768, 10.1016/0002-8703(92)90288-7 · DOI

Sorted by citations

Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
“In an effort to offload TG from remnant lipoproteins (VLDL 2+3 and IDL; RLPs), CETP is activated and promotes an exchange of TG out of RLPs and incorporates CE from HDL and LDL particles [213].”
Background
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Self-citation
Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature
Messina, M. (2016) · Nutrients · doi:10.3390/nu8120754 · Cited by 537
Effects of aerobic exercise on lipids and lipoproteins
Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells
Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M. G., Thacker, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4292 · Cited by 428
Self-citation

See all 336

Authors: Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., Karas, R. H., Kontush, A., Krauss, R. M., Miller, M., & Rader, D. J.
Affiliations: CGH Medical Center (US)
The Heart Research Institute (AU)
Icahn School of Medicine at Mount Sinai (US)
Albany Medical College (US)
Inserm (FR)
University of Pennsylvania (US)
University of Chicago (US)
University of Cincinnati (US)
University of Washington (US)
Tufts University (US)
University of California, San Francisco (US)
University of Maryland, Baltimore (US)
Corresponding author: Toth, Peter P.
ORCID: Toth, Peter P.
Rosenson, Robert S.
Boden, William E.
Chapman, M. John
Cuchel, Marina
Davidson, Michael H.
Davidson, W. Sean
Heinecke, Jay W.
Karas, Richard H.
Kontush, Anatol
Krauss, Ronald M.
Miller, Michael
Rader, Daniel J.
Venue: Journal of Clinical Lipidology
Publisher: Elsevier BV
Published: 2013-09
Volume: 7
Issue: 5
Pages: 484-525
ISSN: 1876-4789 (ISSN-L)
1933-2874
DOI: 10.1016/j.jacl.2013.08.001
OpenAlex: W2106601510
Cited by: 336
References: 282
Citations by year: 2026: 6 · 2025: 21 · 2024: 10 · 2023: 21 · 2022: 34 · 2021: 24 · 2020: 38 · 2019: 25 · 2018: 28 · 2017: 26 · 2016: 19 · 2015: 41 · 2014: 41 · 2013: 2
FWCI: 33.82
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of clinical lipidology (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (R01HL112625)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: HDL cholesterol, cardiovascular risk, atherosclerosis, LDL cholesterol, non-HDL cholesterol, risk stratification
MeSH terms: Animals, Cardiovascular Diseases, Humans, Lipoproteins, HDL, Risk Factors, Societies, Scientific, Consensus, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-density lipoproteins: A consensus statement from the National Lipid Association

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks